tradingkey.logo

MannKind Corp

MNKD

5.610USD

+0.220+4.08%
Fechamento 09/18, 16:00ETCotações atrasadas em 15 min
1.72BValor de mercado
52.40P/L TTM
Mais detalhes de MannKind Corp Empresa
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Informações da empresa
Código da empresaMNKD
Nome da EmpresaMannKind Corp
Data de listagemJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Número de funcionários407
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 28
Endereço1 Casper Street
CidadeDANBURY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal06810
Telefone18186615000
Sitehttps://mannkindcorp.com/
Código da empresaMNKD
Data de listagemJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Christine Mundkur, J.D.
Ms. Christine Mundkur, J.D.
Independent Director
Independent Director
27.68K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
24.46K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
47.79M
60.99%
Royalties
30.00M
38.29%
Services
558.00K
0.71%
Por RegiãoUSD
Nome
Receita
Proporção
United States
78.35M
100.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
47.79M
60.99%
Royalties
30.00M
38.29%
Services
558.00K
0.71%
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.69%
The Vanguard Group, Inc.
5.90%
State Street Global Advisors (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.29%
Outro
78.15%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.69%
The Vanguard Group, Inc.
5.90%
State Street Global Advisors (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.29%
Outro
78.15%
Tipos de investidores
Investidores
Proporção
Investment Advisor
23.14%
Investment Advisor/Hedge Fund
17.87%
Hedge Fund
10.75%
Research Firm
3.13%
Individual Investor
1.74%
Bank and Trust
0.63%
Pension Fund
0.31%
Insurance Company
0.04%
Venture Capital
0.03%
Outro
42.37%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
477
184.37M
60.10%
+2.23M
2025Q1
482
184.47M
60.73%
+2.52M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
2023Q1
412
147.80M
55.93%
-4.58M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
21.45M
7.06%
+246.00K
+1.16%
Mar 31, 2025
The Vanguard Group, Inc.
17.26M
5.68%
+1.26M
+7.90%
Mar 31, 2025
State Street Global Advisors (US)
9.47M
3.12%
-477.80K
-4.80%
Mar 31, 2025
Geode Capital Management, L.L.C.
6.79M
2.23%
+411.83K
+6.46%
Mar 31, 2025
Nitorum Capital, L.P.
7.79M
2.56%
-961.61K
-10.99%
Mar 31, 2025
Two Sigma Investments, LP
7.11M
2.34%
+839.90K
+13.40%
Mar 31, 2025
Avoro Capital Advisors LLC
8.75M
2.88%
--
--
Mar 31, 2025
Millennium Management LLC
5.82M
1.92%
+2.38M
+68.90%
Mar 31, 2025
Qube Research & Technologies Ltd
3.24M
1.07%
+1.70M
+109.83%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
3.53M
1.16%
+567.14K
+19.17%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI